Neutrophil Membrane‐Camouflaged Polyprodrug Nanomedicine for Inflammation Suppression in Ischemic Stroke Therapy

• DOI: 10.1002/adma.202311803
• Publication Date: 2024-03-23T00:40:10Z
• Authors: Ya Zhao; Qian Li; Jingyan Niu; Erliang Guo; Chenchen Zhao; Jian Zhang; Xue Liu; Lihua Wang; Lang Rao; Xiaoyuan Chen; Kuikun Yang
• Keywords: Stroke

Abstract Neuroinflammation has emerged as a major concern in ischemic stroke therapy because it exacebates neurological dysfunction and suppresses recovery after ischemia/reperfusion. Fingolimod hydrochloride (FTY720) is an FDA‐approved anti‐inflammatory drug which exhibits potential neuroprotective effects brain parenchyma. However, delivering sufficient amount of FTY720 through the blood–brain barrier into lesions without inducing severe cardiovascular side remains challenging. Here, neutrophil membrane‐camouflaged polyprodrug nanomedicine that can migrate tissues situ release response to elevated levels reactive oxygen species. This delivers 15.2‐fold more significantly reduces risk cardiotoxicity infection compared with intravenously administered free drug. In addition, single‐cell RNA‐sequencing analysis identifies attenuates poststroke inflammation by reprogramming microglia toward phenotypes, realized via modulating Cebpb‐regulated activation NLRP3 inflammasomes secretion CXCL2 chemokine. study offers new insights design fabrication nanomedicines for effective suppression therapy.